Pharma not prepared for changing health care landscape

Public attention for the last few weeks has rightly focused on the inexcusable mistakes that accompanied the Affordable Care Act’s rollout.

Public attention for the last few weeks has rightly focused on the inexcusable mistakes that accompanied the Affordable Care Act’s rollout.  While the pharmaceutical industry spent several years preparing for the ACA, managements at most of the companies remain flatfooted amidst a few other trends that will likely create more serious problems for them than Obamacare.

For example, the astute pharma journalist, Ed Silverman, recently listed (see here) some of the reasons why the Affordable Care Act might either boost revenues for branded pharma companies or create some hazards.  The potential benefits come from insuring more people, thereby putting them in a better position to buy pharma’s products.  At the same time, Silverman notes that Obamacare’s likely use of data analysis to better determine drug cost-effectiveness represents a distinct threat.  The use of Big Data analysis to determine which medications work best for which patients under what particular circumstances can powerfully obstruct pharma’s efforts to differentiate its brands and justify their exorbitant costs.

See on www.philly.com

From Pharmaceutical Industry digital vision

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s